Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|March 8, 2021
Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferaseDaniel H O' Donovan, Clare Gregson, Martin J Packer, et al.
Journal of Medicinal Chemistry|July 11, 2024
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate CancerSharan K Bagal, Peter C Astles, Coura Diène, et al.
Bioorganic & Medicinal Chemistry|December 13, 2018
The discovery and optimization of benzimidazoles as selective Na<sub>V</sub>1.8 blockers for the treatment of painAlan D Brown, Sharan K Bagal, Paul Blackwell, et al.
ACS Medicinal Chemistry Letters|October 15, 2025
Focused Structure-Based Virtual Screening Identifies Novel Inhibitors of SOS1Silvia Bonomo, Floriane Gibault, Sharan K Bagal, et al.
Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and <i>in Vivo</i> Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.
ACS Medicinal Chemistry Letters|June 24, 2015
Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of PainSharan K Bagal, Peter J Bungay, Stephen M Denton, et al.
Journal of Medicinal Chemistry|June 16, 2026
Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent CancersSharan K Bagal, Coura R N Diène, Sandra Stefanovic-Barrett, et al.
Journal of Medicinal Chemistry|April 20, 2018
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase InhibitorsSharan K Bagal, Kiyoyuki Omoto, David C Blakemore, et al.
Journal of Medicinal Chemistry|November 22, 2021
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 MethyltransferaseSharan K Bagal, Clare Gregson, Daniel H O' Donovan, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Pageof 8